基因治療合作與許可協議（2016-2026）

基因治療交易的權威基準

基因治療領域的合作是由變革性和深遠的治療方法所驅動的，其合約結構反映了複雜的開發過程、製造挑戰以及產生重大長期價值的潛力。

本報告對超過 850 項基因治療合作及許可協議進行了全面系統的分析，清晰且基於證據地展示了整個市場夥伴關係的設計、談判和執行方式。

清楚了解市場標準

本報告對基因治療領域的合約實際構成方式進行了精確闡述。

• 類似交易的可靠基準
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
• 定義切合實際的市場參數
• 清楚洞察基於治療方法類型、開發階段和合作夥伴情況的合約條款差異。
• 支持基於證據的評估和合約結構確定。
• 讓內部討論基於實際交易數據，而不是僅基於假設。
• 了解主要公司的交易方式
• 將整個高價值、快速發展的治療領域中的合作夥伴行為模式和重複性合約結構視覺化。
• 完全透明地了解合約的結構和執行情況
• 本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和付款條款
• 關鍵合約條款和保護措施
• 這種程度的透明度對於了解基因治療夥伴關係中價值、風險和控制權的分配方式至關重要，尤其是在與生產規模擴大、監管複雜性和長期患者療效相關的領域。
• 專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

• 在先進治療領域設計和評估交易
• 在清晰的市場環境下準備談判
• 對許可、合作開發和平台合作關係進行評估。
• 利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

• 超過850項基因治療合作及授權協議
• 財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
• 可全文搜尋的合約目錄（依公司、治療方法及開發階段）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 合約趨勢、重大交易和活躍合約方分析。
• 基因治療交易的可靠依證參考資料
• 本報告結合了全面的合約資料覆蓋和詳細的合約層面分析，為基因治療領域的夥伴關係的建立、談判和評估提供了可靠的、依證的資源。

目錄

執行摘要

第1章：引言

第2章：基因治療領域的交易趨勢

• 過去幾年基因療法合作
• 基因治療產業中最活躍的參與者
• 基因治療合約：按合約類型分類
• 基因治療合約：按治療領域分類
• 基因治療合約：按行業分類
• 基因治療合約的條件
  • 標題金額
  • 預付款
  • 里程碑付款
  • 權利金費率

第3章 重大基因治療合約

• 按合約價值排名的前幾大基因療法合約

第4章：基因治療最活躍領域的締約方

• 基因治療領域最活躍的締約方
• 基因治療領域最活躍的簽約方的公司簡介

第5章 基因治療合約目錄

• 基因治療合約目錄

第6章 基因治療合約：依技術類型分類

• 合約目錄
• 合約目錄：基因治療合約（依公司名稱排序，A-Z）
• 合約目錄：按合約類型分類的基因治療合約
• 合約目錄：按治療領域分類的基因治療合約
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• 關於當前合作夥伴關係
• 關於現行協議
• Current Partnering 最新報告列表

The definitive benchmark for gene therapy dealmaking

Gene therapy partnering is driven by transformative, high-impact therapeutic approaches, with deal structures reflecting complex development pathways, manufacturing challenges, and significant long-term value potential.

This report provides a comprehensive and structured analysis of 850+ gene therapy collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how gene therapy deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by therapy type, development stage, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a high-value and rapidly evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within gene therapy partnerships, particularly in areas involving manufacturing scale-up, regulatory complexity, and long-term patient outcomes.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark advanced therapy transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing, co-development, and platform partnerships
• Support internal strategy with robust, defensible data
• What's included
• 850+ gene therapy collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy type, and development stage)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for gene therapy dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how gene therapy partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene therapy dealmaking

• 2.1. Introduction
• 2.2. Gene therapy deals over the years
• 2.3. Most active gene therapy dealmakers
• 2.4. Gene therapy deals by deal type
• 2.5. Gene therapy deals by therapy area
• 2.6. Gene therapy deals by industry sector
• 2.7. Deal terms for gene therapy deals
  • 2.7.1 Gene therapy deals headline values
  • 2.7.2 Gene therapy deal upfront payments
  • 2.7.3 Gene therapy deal milestone payments
  • 2.7.4 Gene therapy royalty rates

Chapter 3 - Leading gene therapy deals

• 3.1. Introduction
• 3.2. Top gene therapy deals by value

Chapter 4 - Most active gene therapy dealmakers

• 4.1. Introduction
• 4.2. Most active gene therapy dealmakers
• 4.3. Most active gene therapy deals company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

• Deal directory
• Deal directory - Gene therapy deals by company A-Z
• Deal directory - Gene therapy deals by deal type
• Deal directory - Gene therapy deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gene therapy deals since 2016
• Figure 2: Active gene therapy dealmaking activity since 2016
• Figure 3: Gene therapy deals by deal type since 2016
• Figure 4: Gene therapy deals by therapy area since 2016
• Figure 5: Gene therapy deals by industry sector since 2016
• Figure 6: Gene therapy deals with a headline value
• Figure 7: Gene therapy deals with an upfront value
• Figure 8: Gene therapy deals with a milestone value
• Figure 9: Gene therapy deals with a royalty rate value
• Figure 10: Top gene therapy deals by value since 2016
• Figure 11: Most active gene therapy dealmakers since 2016
• Figure 12: Gene therapy deals by technology type since 2016